News | August 18, 2022
ProBioGen enters into master service agreement with NextPoint Therapeutics
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
The integrated services ensure that NextPoint can bring their molecule to the clinic in a timely manner.
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Results consistent with previous trials, reinforcing benefit of Daiichi Sankyo and AstraZeneca’s ENHERTU in previously treated patients
Based on DESTINY-Lung02 results which showed AstraZeneca and Daiichi Sankyo’s Enhertu reported a confirmed objective response rate of 57.7% in patients with HER2-mutant disease
Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate
Company raises the annual revenue guidance from mid-teens to high teens
Subscribe To Our Newsletter & Stay Updated
